Biblio Discovery — Demo Discovery Service

24 results for "Adam Mor"

Showing 1–20 · 0.55 seconds · RSS

  1. Journal Article

    Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1

    Adam Mor; Marianne Strazza

    Frontiers in Cell and Developmental Biology, Vol. 9 · 2022 · English · DOAJ Scopus

    The emergence of anti–cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), anti–programmed cell death 1 ligand (anti–PD-1), and anti–PD-L1 antibodies as immune checkpoint inhibitors (ICIs) revolutionized the treatment of numerous types of tumors. These antibodies, both alone and in combination, provide…

  2. Journal Article

    SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity

    Yevgeniya Gartshteyn; Anca D. Askanase; Adam Mor

    Frontiers in Immunology, Vol. 12 · 2021 · English · DOAJ Scopus

    T cell activation is the result of the integration of signals across the T cell receptor and adjacent co-receptors. The signaling lymphocyte activation molecules (SLAM) family are transmembrane co-receptors that modulate antigen driven T cell responses. Signal transduction downstream of the SLAM…

  3. Journal Article

    Combination Approaches to Target PD-1 Signaling in Cancer

    Emily K. Moore; Marianne Strazza; Adam Mor

    Frontiers in Immunology, Vol. 13 · 2022 · English · DOAJ Scopus

    Cancer remains the second leading cause of death in the US, accounting for 25% of all deaths nationwide. Immunotherapy techniques bolster the immune cells’ ability to target malignant cancer cells and have brought immense improvements in the field of cancer treatments. One important inhibitory…

  4. Journal Article

    Immunohistochemistry of Immune Cells and Cells Bound to in vivo Administered Antibodies in Liver, Lung, Pancreas, and Colon of B6/lpr Mice

    Kieran Adam; Adam Mor

    Bio-Protocol, Vol. 12 No. 14 · 2022 · English · DOAJ Scopus

    Employing a novel mouse model of immune related adverse events (irAEs) induced by combination of anti-PD1 and anti-CTLA-4 antibodies, we visualized immune infiltration into the liver, lung, pancreas, and colon. Here, we describe the avidin-biotin conjugate (ABC) method used to stain T cells (CD4…

  5. Journal Article

    Data on the identification of VRK2 as a mediator of PD-1 function

    Michael Peled; Kieran Adam; Adam Mor

    Data in Brief, Vol. 37 · 2021 · English · DOAJ Scopus

    Therapeutic programmed cell death protein 1 (PD-1) blockade enhances T cell mediated anti-tumor immunity, but many patients do not respond, and a significant proportion develops inflammatory toxicities. To develop better therapeutics and to understand the signaling pathways downstream of PD-1 we…

  6. Journal Article

    An Imaging-Based Assay to Measure the Location of PD-1 at the Immune Synapse for Testing the Binding Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies

    Justin Zhong; Shalom Lerrer; Adam Mor

    Bio-Protocol, Vol. 14 No. 17 · 2024 · English · DOAJ Scopus

    PD-1 is an immune checkpoint on T cells. Antibodies to PD-1 or its ligand PD-L1 are gaining popularity as a leading immunotherapy approach. In the US, 40% of all cancer patients will be treated with anti-PD-1 or anti-PD-L1 antibodies but, unfortunately, only 30% will respond, and many will develop…

  7. Journal Article

    SAP-expressing T peripheral helper cells identify systemic lupus erythematosus patients with lupus nephritis

    Yevgeniya Gartshteyn; Laura Geraldino-Pardilla; Leila Khalili et al.

    Frontiers in Immunology, Vol. 15 · 2024 · English · DOAJ Scopus

    IntroductionT follicular (TFH) and peripheral helper (TPH) cells have been increasingly recognized as a pathogenic subset of CD4 T cells in systemic lupus erythematosus (SLE). The SLAM Associated Protein (SAP) regulates TFH and TPH function by binding to the co-stimulatory signaling lymphocyte…

  8. Journal Article Full text

    A novel mouse model for checkpoint inhibitor-induced adverse events.

    Kieran Adam; Alina Iuga; Anna S Tocheva et al.

    PLoS ONE, Vol. 16 No. 2 · 2021 · English · DOAJ Scopus

    Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a variety of cancers, however their therapeutic potential is limited by abstruse immune related adverse events. Currently, no robust animal model exists of checkpoint inhibitor-induced adverse events…

    Also available at: PLOS

  9. Journal Article Full text

    Structure-function analysis of nucleolin and ErbB receptors interactions.

    Keren Farin; Ayelet Di Segni; Adam Mor et al.

    PLoS ONE, Vol. 4 No. 7 · 2009 · English · DOAJ Scopus

    BackgroundThe ErbB receptor tyrosine kinases and nucleolin are major contributors to malignant transformation. Recently we have found that cell-surface ErbB receptors interact with nucleolin via their cytoplasmic tail. Overexpression of ErbB1 and nucleolin leads to receptor phosphorylation…

    Also available at: PLOS

  10. Journal Article

    PD-1-stimulated T cell subsets are transcriptionally and functionally distinct

    Shalom Lerrer; Anna S. Tocheva; Shoiab Bukhari et al.

    iScience, Vol. 24 No. 9 · 2021 · English · DOAJ Scopus

    Summary: Despite the obvious inhibitory outcome of PD-1 signaling, an additional series of functions are activated. We have observed that T cells stimulated through the T cell receptor (TCR) and PD-1 primarily do not proliferate; however, there is a population of cells that proliferates more than…

  11. Journal Article

    Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells

    Marianne Strazza; Inbar Azoulay-Alfaguter; Michael Peled et al.

    Communications Biology, Vol. 4 No. 1 · 2021 · English · DOAJ Scopus

    Strazza et al. show that phosphoprotein associated with glycosphingolipidenriched microdomains 1 (PAG) is phosphorylated following PD-1 ligation. They find that PAG deletion sensitizes tumors to PD-1 blockade. This study suggests PAG as a critical mediator of PD-1 signaling and a promising target…

  12. Journal Article

    Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth

    Marianne Strazza; Emily K. Moore; Kieran Adam et al.

    Molecular Therapy: Methods & Clinical Development, Vol. 27 · 2022 · English · DOAJ

    The transmembrane adaptor phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG) is phosphorylated in T cells downstream of PD-1 signaling and contributes to the resulting functional inhibition of multiple cellular processes. Furthermore, PAG expression is negatively…

  13. Journal Article Full text

    SLAMF6 clustering is required to augment T cell activation

    Matthew A. Dragovich; Kieran Adam; Marianne Strazza et al.

    PLOS ONE, Vol. 14 No. 6 · 2019 · English · PLOS Scopus

    The signaling lymphocytic activation molecule (SLAM) family is comprised of nine distinct receptors that are expressed exclusively on hematopoietic cells. Most of these transmembrane receptors are homotypic by nature and downstream signaling occurs when cells that express the same SLAM receptor…

    Also available at: DOAJ

  14. Journal Article

    SLAMF6 compartmentalization enhances T cell functions

    Yevgeniya Gartshteyn; Anca D Askanase; Ruijiang Song et al.

    Life Science Alliance, Vol. 6 No. 2 · 2023 · English · DOAJ Scopus

    After stimulation, the T cell co-receptor SLAMF6 colocalizes with the TCR–CD3 complex to enhance T cell activation. Targeting SLAMF6 localization and function with bispecific antibodies is a novel mechanism with potential therapeutic translation. Signaling lymphocyte activation molecule family…

  15. Journal Article

    Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma

    Karen Gambina; Carly Tymm; Matthieu Paiola et al.

    Frontiers in Immunology, Vol. 17 · 2026 · English · DOAJ Scopus

    Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) is an uncommon immune-related adverse event (irAE) associated with the use of immune checkpoint inhibitors for the treatment of malignancies. We present a case of a 77-year-old woman who…

  16. Journal Article

    PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis

    Johanna Straube; Shoiab Bukhari; Shalom Lerrer et al.

    Arthritis Research & Therapy, Vol. 26 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Background PD-1 is an immune checkpoint on T cells, and interventions to block this receptor result in T cell activation and enhanced immune response to tumors and pathogens. Reciprocally, despite a decade of research, approaches to treat autoimmunity with PD-1 agonists have only had…

  17. Journal Article

    Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity

    Brian S Henick; Xizi Hu; Shoiab M Bukhari et al.

    Journal for ImmunoTherapy of Cancer, Vol. 12 No. 3 · 2024 · English · DOAJ Scopus

    Background Immune checkpoint inhibitors (ICIs) have improved outcomes and extended patient survival in several tumor types. However, ICIs often induce immune-related adverse events (irAEs) that warrant therapy cessation, thereby limiting the overall effectiveness of this class of therapeutic…